CN113777316A - Application of urinary C4b-binding protein α chain and its polypeptide fragments in burns - Google Patents
Application of urinary C4b-binding protein α chain and its polypeptide fragments in burns Download PDFInfo
- Publication number
- CN113777316A CN113777316A CN202010520277.2A CN202010520277A CN113777316A CN 113777316 A CN113777316 A CN 113777316A CN 202010520277 A CN202010520277 A CN 202010520277A CN 113777316 A CN113777316 A CN 113777316A
- Authority
- CN
- China
- Prior art keywords
- binding protein
- urine
- burn
- alpha chain
- protein alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/40—Disorders due to exposure to physical agents, e.g. heat disorders, motion sickness, radiation injuries, altitude sickness, decompression illness
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides an application of urine C4b binding protein alpha chain (C4 b-binding protein alpha chain) and a polypeptide fragment thereof, in particular to an application of urine C4b binding protein alpha chain and a polypeptide fragment thereof in preparation of preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like. The burn is an important common wound in daily life, about 5000-100000 people burn in every 100 million people every year, according to the statistics of the world health organization, more than 30 million people die of burn patients all year around the world, and the survival rate of the serious burn treatment is still at a lower level. The invention proves that urine C4b binding protein alpha chain and polypeptide fragment thereof have higher expression in burn patients compared with healthy people (normal control group). Can be used for various purposes of detecting burn patients. The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine sample, and utilizes the urine sample to detect the urine C4b binding protein alpha chain and the polypeptide fragment thereof.
Description
Technical Field
The invention relates to a new application of urine C4b binding protein alpha chain and a polypeptide fragment thereof, in particular to an application of urine C4b binding protein alpha chain and a polypeptide fragment thereof in burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Background
Burn refers to the injury of skin, tissue and even deep viscera of human body caused by chemical substances such as flame, high-temperature gas, scorching solid or liquid, radioactive rays, electric energy, strong acid and strong alkali, etc., and is a systemic comprehensive disease. After burn, a large amount of reactions such as necrosis, infection, shock, blood coagulation dysfunction and the like of wound tissues can cause a series of pathophysiological changes of organisms. Burns of different degrees have different influences on human bodies, serious burns can damage the environment in the human bodies, the burn patients have pathophysiological changes of complexity of various systems, and relevant detection indexes can correspondingly change along with the difference of the severity of the burns. Timely detection of changes in these indices can provide valuable reference for clinicians in many areas, such as disease diagnosis, disease judgment, treatment selection, and patient prognosis assessment.
However, patients with severe burns have poor skin integrity, and clinical use of hematological tests as invasive tests on the skin in such patients has presented difficulties, and repeated blood draw tests can also exacerbate patient pain. Urine as ultrafiltrate of blood contains abundant biological information, and the collection process has the advantages of non-invasive and convenient operation, and the like, which is particularly obvious in the detection of burn patients. The biomarker which is helpful for burn diagnosis and reflects disease change is searched in urine, so that the life quality and compliance of burn patients can be improved, the pain of blood collection for many times is relieved, and a reference basis which is favorable for disease diagnosis and treatment is better provided for clinicians.
The C4b binding protein alpha chain (C4 b-binding protein alpha chain, C4 bp) controls the classical pathway of complement activation. It acts as a cofactor and acts in combination with a C3b/C4b inactivator to inactivate the complement fragment C4 b. It also accelerates the degradation of the C4bC2a complex (C3 convertase) by dissociating the complement fragment C2 a. Alpha chain bound C4b also interacts with anticoagulant protein S and serum amyloid P. In the study, the alpha chain of the C4b binding protein in the urine of the burn patient is up-regulated compared with that of a healthy human group, and the content of the protein in the urine of the burn patient is increased.
Compared with the common clinical blood sample, the urine can be collected in a non-invasive, continuous and large amount; without homeostatic regulation, more various and larger changes can be accumulated, and many pathophysiological changes of the body can be reflected in urine. Some protein polypeptides with relatively small molecular weight, such as hormones and cytokines, are excreted into urine quickly after entering blood, and the probability that the proteins and polypeptides are detected in urine is much higher than that in blood; before urine is collected, a possible protein degradation process in urine is completed, so that urine protein can be kept stable for a longer time. In order to relieve the pain of multiple blood sampling of burn patients, the experiment is expected to realize the diagnosis and disease monitoring of the burn patients by painless, convenient, quick and easily repeated urine detection through the research of urine protein or polypeptide on the basis of the methodology exploration of the early stage, and also lays a foundation for the further research of the urine polypeptide detection kit.
Disclosure of Invention
The invention aims to provide application of urine C4b binding protein alpha chain and polypeptide fragments thereof in preparation of preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation, mechanism research and the like.
Preferably, the amino acid sequence of the urine C4b binding protein alpha chain is shown in SEQ ID NO.1 (MHPPKTPSGA LHRKRKMAAW PFSRLWKVSD PILFQMTLIA ALLPAVLGNC GPPPTLSFAA PMDITLTETR FKTGTTLKYT CLPGYVRSHS TQTLTCNSDG EWVYNTFCIY KRCRHPGELR NGQVEIKTDL SFGSQIEFSC SEGFFLIGST TSRCEVQDRG VGWSHPLPQC EIVKCKPPPD IRNGRHSGEE NFYAYGFSVT YSCDPRFSLL GHASISCTVE NETIGVWRPS PPTCEKITCR KPDVSHGEMV SGFGPIYNYK DTIVFKCQKG FVLRGSSVIH CDADSKWNPS PPACEPNSCI NLPDIPHASW ETYPRPTKED VYVVGTVLRY RCHPGYKPTT DEPTTVICQK NLRWTPYQGC EALCCPEPKL NNGEITQHRK SRPANHCVYF YGDEISFSCH ETSRFSAICQ GDGTWSPRTP SCGDICNFPP KIAHGHYKQS SSYSFFKEEI IYECDKGYIL VGQAKLSCSY SHWSAPAPQC KALCRKPELV NGRLSVDKDQ YVEPENVTIQ CDSGYGVVGP QSITCSGNRT WYPEVPKCEW ETPEGCEQVL TGKRLMQCLP NPEDVKMALE VYKLSLEIEQ LELQRDSARQ STLDKEL); or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO. 1.
Preferably, the preparation is a detection kit for the urine C4b binding protein alpha chain and polypeptide fragments thereof of burn patients.
Preferably, the kit comprises one or more of an immunization method for antigen-antibody reaction and kits thereof such as aptamer antibodies or antibody fragments capable of specifically binding to C4b binding protein alpha chain and polypeptide fragments thereof.
Preferably, the detection method comprises a mass spectrometry method for directly detecting the alpha chain of the C4b binding protein and a polypeptide fragment thereof and a related kit thereof.
Preferably, the detection method comprises related nucleic acid detection methods for directly detecting the alpha chain of the C4b binding protein and polypeptide fragments thereof and related kits.
Preferably, the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and the second antibody diluent.
Preferably, the standard comprises a C4b binding protein alpha chain standard, a humanized tag antibody standard; preferably, the quality control product comprises: c4b binding protein alpha chain quality control product and humanized label antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
Preferably, the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide and cellulose, and has similar functions.
The inventor firstly collects urine samples of healthy people and burn patients, centrifugates for 5min at 4000r/min, absorbs supernatant, measures the concentration of extracted protein by a Bradford method, and carries out SDS-PAGE enzymolysis. The Label-free mass spectrometry of the urine samples was performed by the OrbitrapFasion type mass spectrometer. And performing quantitative calculation on data obtained in the mass spectrum of the burn group and the normal control group. The differential polypeptide is screened by using the difference of protein expression amount more than 1.5 times and P <0.05 as a reference standard through statistical test. Then, the inventors identified the statistically significant differential polypeptides, and searched the database to obtain the alpha chain of the binding protein of the differential protein C4 b.
Compared with healthy people, the C4b binding protein alpha chain and the polypeptide fragment thereof are high in expression in urine of burn patients and have better consistency with clinical diagnosis. Therefore, the detection of urine C4b binding protein alpha chain and polypeptide fragments thereof can be used for auxiliary diagnosis or disease monitoring of burns.
The invention exerts the advantages of noninvasive acquisition, large-scale repeated sampling and convenient preservation of the urine sample, and utilizes the urine sample to detect the urine C4b binding protein alpha chain and the polypeptide fragment thereof.
In order to make the aforementioned and other objects, features and advantages of the present invention comprehensible, preferred embodiments accompanied with figures are described in detail below.
Drawings
FIG. 1 is a graph of the content of urine C4b binding protein alpha chain and its polypeptide fragment in burn group and healthy control group.
FIG. 2 is a schematic representation of the C4b binding protein alpha chain involved in major biological processes.
Detailed Description
Example 1Collection and processing of urine specimens
Burn patients were selected as the burn group, and contemporary physical examiners were selected as the normal control group. 30ml samples of fresh morning urine were collected from each group of subjects after admission, and those who failed to urinate normally collected their morning urine from their catheters and placed in dry, clean containers. Centrifuging the collected urine specimen at 4000r/min for 5min, sucking supernatant, subpackaging 2ml per tube, and storing in a refrigerator at-80 ℃.
Example 2Mass spectrometry and screening of urine polypeptides
Extracting protein from urine sample, and determining the concentration of extracted protein. Mass spectrometry of urine samples was performed by orbitrapfuision type mass spectrometry. And performing quantitative calculation on data obtained in the mass spectrum of the experimental group and the normal control group. The comparison among groups adopts t-test to carry out differential analysis, and differential expression proteins are screened by using the difference of protein expression quantity more than 1.5 times and taking the statistical test that P <0.05 as a reference standard.
Example 3Identification and analysis of differential Polypeptides
The used database is a Unit _ Homo database, the generated mass spectrum original file is processed by MaxQuant software, and the retrieval parameter setting is shown in Table 1.
Compared with healthy people, the C4b binding protein alpha chain is highly expressed in urine of burn patients as shown in figure 1, the main biological processes involved in the urine are shown in figure 2, and the expression of the C4b binding protein alpha chain in urine of normal control groups and burn groups is significantly different.
Although the present invention has been described with respect to the preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.
Sequence listing
<110> Zhang Man
<120> urine C4b binding protein alpha chain and application of polypeptide fragment thereof in burn
<130> 1
<140> 20PC4bp
<141> 2020-05-10
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 597
<212> PRT
<213> Human Urine
<400> 1
Met His Pro Pro Lys Thr Pro Ser Gly Ala Leu His Arg Lys Arg Lys
1 5 10 15
Met Ala Ala Trp Pro Phe Ser Arg Leu Trp Lys Val Ser Asp Pro Ile
20 25 30
Leu Phe Gln Met Thr Leu Ile Ala Ala Leu Leu Pro Ala Val Leu Gly
35 40 45
Asn Cys Gly Pro Pro Pro Thr Leu Ser Phe Ala Ala Pro Met Asp Ile
50 55 60
Thr Leu Thr Glu Thr Arg Phe Lys Thr Gly Thr Thr Leu Lys Tyr Thr
65 70 75 80
Cys Leu Pro Gly Tyr Val Arg Ser His Ser Thr Gln Thr Leu Thr Cys
85 90 95
Asn Ser Asp Gly Glu Trp Val Tyr Asn Thr Phe Cys Ile Tyr Lys Arg
100 105 110
Cys Arg His Pro Gly Glu Leu Arg Asn Gly Gln Val Glu Ile Lys Thr
115 120 125
Asp Leu Ser Phe Gly Ser Gln Ile Glu Phe Ser Cys Ser Glu Gly Phe
130 135 140
Phe Leu Ile Gly Ser Thr Thr Ser Arg Cys Glu Val Gln Asp Arg Gly
145 150 155 160
Val Gly Trp Ser His Pro Leu Pro Gln Cys Glu Ile Val Lys Cys Lys
165 170 175
Pro Pro Pro Asp Ile Arg Asn Gly Arg His Ser Gly Glu Glu Asn Phe
180 185 190
Tyr Ala Tyr Gly Phe Ser Val Thr Tyr Ser Cys Asp Pro Arg Phe Ser
195 200 205
Leu Leu Gly His Ala Ser Ile Ser Cys Thr Val Glu Asn Glu Thr Ile
210 215 220
Gly Val Trp Arg Pro Ser Pro Pro Thr Cys Glu Lys Ile Thr Cys Arg
225 230 235 240
Lys Pro Asp Val Ser His Gly Glu Met Val Ser Gly Phe Gly Pro Ile
245 250 255
Tyr Asn Tyr Lys Asp Thr Ile Val Phe Lys Cys Gln Lys Gly Phe Val
260 265 270
Leu Arg Gly Ser Ser Val Ile His Cys Asp Ala Asp Ser Lys Trp Asn
275 280 285
Pro Ser Pro Pro Ala Cys Glu Pro Asn Ser Cys Ile Asn Leu Pro Asp
290 295 300
Ile Pro His Ala Ser Trp Glu Thr Tyr Pro Arg Pro Thr Lys Glu Asp
305 310 315 320
Val Tyr Val Val Gly Thr Val Leu Arg Tyr Arg Cys His Pro Gly Tyr
325 330 335
Lys Pro Thr Thr Asp Glu Pro Thr Thr Val Ile Cys Gln Lys Asn Leu
340 345 350
Arg Trp Thr Pro Tyr Gln Gly Cys Glu Ala Leu Cys Cys Pro Glu Pro
355 360 365
Lys Leu Asn Asn Gly Glu Ile Thr Gln His Arg Lys Ser Arg Pro Ala
370 375 380
Asn His Cys Val Tyr Phe Tyr Gly Asp Glu Ile Ser Phe Ser Cys His
385 390 395 400
Glu Thr Ser Arg Phe Ser Ala Ile Cys Gln Gly Asp Gly Thr Trp Ser
405 410 415
Pro Arg Thr Pro Ser Cys Gly Asp Ile Cys Asn Phe Pro Pro Lys Ile
420 425 430
Ala His Gly His Tyr Lys Gln Ser Ser Ser Tyr Ser Phe Phe Lys Glu
435 440 445
Glu Ile Ile Tyr Glu Cys Asp Lys Gly Tyr Ile Leu Val Gly Gln Ala
450 455 460
Lys Leu Ser Cys Ser Tyr Ser His Trp Ser Ala Pro Ala Pro Gln Cys
465 470 475 480
Lys Ala Leu Cys Arg Lys Pro Glu Leu Val Asn Gly Arg Leu Ser Val
485 490 495
Asp Lys Asp Gln Tyr Val Glu Pro Glu Asn Val Thr Ile Gln Cys Asp
500 505 510
Ser Gly Tyr Gly Val Val Gly Pro Gln Ser Ile Thr Cys Ser Gly Asn
515 520 525
Arg Thr Trp Tyr Pro Glu Val Pro Lys Cys Glu Trp Glu Thr Pro Glu
530 535 540
Gly Cys Glu Gln Val Leu Thr Gly Lys Arg Leu Met Gln Cys Leu Pro
545 550 555 560
Asn Pro Glu Asp Val Lys Met Ala Leu Glu Val Tyr Lys Leu Ser Leu
565 570 575
Glu Ile Glu Gln Leu Glu Leu Gln Arg Asp Ser Ala Arg Gln Ser Thr
580 585 590
Leu Asp Lys Glu Leu
595
Claims (9)
1. The urine C4b binding protein alpha chain and its polypeptide fragment can be used for preparing preparations for burn diagnosis, differential diagnosis, burn area and degree evaluation, treatment effect evaluation, monitoring, prognosis evaluation and mechanism research.
2. The use of claim 1, wherein the urine C4b binding protein has the amino acid sequence of the α chain as shown in SEQ ID No. 1; or an amino acid sequence which is derived from the amino acid sequence shown in SEQ ID NO.1 and has the same function with the amino acid sequence shown in SEQ ID NO. 1.
3. The use of claim 1, wherein the preparation is a test kit for detecting C4b-binding protein alpha chain and its polypeptide fragments in urine of burn patients.
4. Use according to claim 3, wherein the kit comprises one or more of an immunological method of antigen-antibody reaction and kits thereof, such as aptamer antibodies or antibody fragments capable of specifically binding to the alpha chain of C4b binding protein and polypeptide fragments thereof.
5. The use according to claim 3, wherein the detection method comprises mass spectrometry and related kits for directly detecting C4b-binding protein alpha chain and its polypeptide fragment.
6. The use of claim 3, wherein the detection method comprises a method for directly detecting C4b binding protein alpha chain and its polypeptide fragment or its related nucleic acid detection, and its related kit.
7. The use according to claim 3, wherein the kit further comprises a component selected from the group consisting of: the kit comprises a solid phase carrier, a diluent, a reference substance, a standard substance, a quality control substance, a detection antibody, a second antibody diluent, a luminescent reagent, a washing solution, a color development solution and a stop solution, wherein the solid phase carrier is any one or a combination of a plurality of the solid phase carrier, the diluent, the reference substance, the standard substance, the quality control substance, the detection antibody, the second antibody and the second antibody diluent.
8. The use of claim 7, wherein the standard comprises a C4b binding protein a chain standard, a humanized tag antibody standard; preferably, the quality control product comprises: c4b binding protein alpha chain control product and humanized label antibody quality control product; preferably, the solid support comprises: particles, microspheres, glass slides, test strips, plastic beads, liquid phase chips, micro-porous plates or affinity membranes and other carriers with the same functions.
9. The use of claim 8, wherein the solid phase carrier is made of any one of polyvinyl chloride, polystyrene, polyacrylamide, cellulose, and carriers with similar functions.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010520277.2A CN113777316A (en) | 2020-06-09 | 2020-06-09 | Application of urinary C4b-binding protein α chain and its polypeptide fragments in burns |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010520277.2A CN113777316A (en) | 2020-06-09 | 2020-06-09 | Application of urinary C4b-binding protein α chain and its polypeptide fragments in burns |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113777316A true CN113777316A (en) | 2021-12-10 |
Family
ID=78834506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010520277.2A Pending CN113777316A (en) | 2020-06-09 | 2020-06-09 | Application of urinary C4b-binding protein α chain and its polypeptide fragments in burns |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113777316A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011005878A1 (en) * | 2010-03-22 | 2011-12-01 | Wilfried P. Bieger | Determining neuromodulatory or mental disorders using arrangements for liquid chromatography, comprises measuring concentrations of neurotransmitters in blood cells and carrying out concentration measurements in thrombocytes |
| CN103842001A (en) * | 2011-12-29 | 2014-06-04 | 阿梅迪卡株式会社 | Integrated kit for separating blood and concentrating prp and method for extracting prp using same |
-
2020
- 2020-06-09 CN CN202010520277.2A patent/CN113777316A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011005878A1 (en) * | 2010-03-22 | 2011-12-01 | Wilfried P. Bieger | Determining neuromodulatory or mental disorders using arrangements for liquid chromatography, comprises measuring concentrations of neurotransmitters in blood cells and carrying out concentration measurements in thrombocytes |
| CN103842001A (en) * | 2011-12-29 | 2014-06-04 | 阿梅迪卡株式会社 | Integrated kit for separating blood and concentrating prp and method for extracting prp using same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113777314A (en) | Application of urinary talin 1 and its polypeptide fragments in burns | |
| CN113777316A (en) | Application of urinary C4b-binding protein α chain and its polypeptide fragments in burns | |
| CN113777313A (en) | Application of urine vitamin K-dependent protein S and polypeptide fragment thereof in burn | |
| CN114113580A (en) | Application of urine thrombomodulin and polypeptide fragment thereof in burn | |
| CN113777304A (en) | Application of urine plasminogen and polypeptide fragment thereof in burn | |
| CN113777302A (en) | Application of urine complement factor D and polypeptide fragment thereof in burn | |
| CN113759123A (en) | Application of urine cartilage intermediate layer protein and polypeptide fragment thereof in burn | |
| CN113759125A (en) | Urinary uteroglobin and application of polypeptide fragments thereof in burn | |
| CN113777303A (en) | Application of urine prothrombin and polypeptide fragment thereof in burn | |
| CN113759122A (en) | Application of urine protein Z and polypeptide fragment thereof in burn | |
| CN113804889A (en) | Application of Urinary Collagen Type XII α1 Chain and Its Polypeptide Fragments in Burns | |
| CN113804891A (en) | Application of Urine C-reactive Protein and Its Polypeptide Fragments in Burns | |
| CN113777331A (en) | Application of urokininogen-1 and polypeptide fragment thereof in burn | |
| CN114113640A (en) | Application of urine blood coagulation factor IX and polypeptide fragment thereof in burn | |
| CN114113600A (en) | Application of urine alpha 1-antitrypsin and polypeptide fragment thereof in burn | |
| CN114113601A (en) | Application of urine heparin cofactor II and polypeptide fragment thereof in burn | |
| CN113777315A (en) | Application of urinary ubiquitin-like protein ISG15 and its polypeptide fragments in burns | |
| CN114113622A (en) | Urine guanine nucleotide binding protein G(s) subunit alpha short subtype and application of polypeptide fragment thereof in burn | |
| CN114113621A (en) | Urine guanine nucleotide binding protein subunit alpha-13 and application of polypeptide fragment thereof in burn | |
| CN113804890A (en) | Application of Urine Programmed Cell Death 6-Interacting Protein and Its Polypeptide Fragments in Burns | |
| CN113804893A (en) | Application of urine type I collagen alpha 1 chain and polypeptide fragment thereof in burn | |
| CN113820485A (en) | Urine carbonic anhydrase 3 and application of polypeptide fragment thereof in burn | |
| CN113777305A (en) | Application of urine monoadenosine diphosphate ribosyltransferase and polypeptide fragment thereof in burn | |
| CN113759133A (en) | Application of urinary angiotensinogen and polypeptide fragment thereof in burn | |
| CN113777306A (en) | Application of urine fructose bisphosphate aldolase B and its polypeptide fragments in burns |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |